Zobrazeno 1 - 10
of 36
pro vyhledávání: ''
Autor:
Francesco Merli, Luca Nassi, Monica Tani, Flavia Salvi, Vincenzo Pavone, Marco Ladetto, Manuela Zanni, Annalisa Peli, Stefano Volpetti, Riccardo Centurioni, Stefano Luminari, Annalisa Arcari, Alessandro Re, Michele Spina, Alessandro Pulsoni, Andrea Evangelista, Anna Marina Liberati, Alessandra Tucci, Roberto Freilone, Gerardo Musuraca, Caterina Patti, Caterina Stelitano, Stefania Massidda
Publikováno v:
Leukemialymphoma. 60(12)
This phase-II study assessed activity and toxicity of substituting conventional doxorubicin with nonpegylated liposomal doxorubicin in the conventional ABVD regimen for the treatment of elderly or cardiopathic patients with HL. Stage I-IIA and IIB-IV
Publikováno v:
Leukemialymphoma. 60(2)
Extranodal natural killer/T-cell lymphoma (ENKTL) is associated with Epstein-Barr virus (EBV) infection, a common cause of hemophagocytosis. As interleukin-18 (IL18) is related with hemophagocytosis, we measured serum IL18 and IL18-related cytokines
Autor:
Claire Dearden, Kim Linton, Michael Potter, John Radford, Patrick Shenjere, Kate Foley, Clare Peckitt, Ian Chau, Lia P Menasce, Mark Ethell, Catherine O'Hara, Hannah Johnson, Andrew Wotherspoon, Binnaz Yasar, David Cunningham, Ayoma D. Attygalle, Adam Gibb, Rebecca Lee, Joanna Dash, Mary Gleeson, Eliza A Hawkes, Morgan Back
Publikováno v:
Leukemialymphoma. 59(7)
We evaluated the outcomes for patients with peripheral T-cell lymphoma (PTCL) undergoing front-line chemotherapy at our institutions between 2002 and 2012. One hundred and fifty-six patients were eligible, comprising PTCL not otherwise specified (NOS
Autor:
Lara Mannelli, Luigi Rigacci, Benedetta Puccini, S. Kovalchuk, Monica Bocchia, Emanuele Cencini, T. Carfagno, Alberto Bosi, Gabriele Simontacchi, Alberto Fabbri, Gemma Benelli
Publikováno v:
Leukemialymphoma. 59(6)
Early-stage follicular lymphoma (FL) can be cured with involved-field radiotherapy (IF-RT); however, many patients relapse in non-irradiated areas. A combined association with chemotherapy could increase treatment efficacy, but toxic effects could be
Autor:
Ivan Dlouhy, Elias Campo, Laura Magnano, Eva Giné, Alejandra Martínez-Trillos, Antonio Martínez, Armando López-Guillermo, Neus Villamor, Tycho Baumann, Jordina Rovira, Joaquim Carreras, Olga Balagué
Publikováno v:
Leukemialymphoma. 58(4)
We have analyzed in lymph nodes at diagnosis of 75 patients with follicular lymphoma (FL) the relationship between different T-cell subpopulations, assessed by immunohistochemistry (IHC) and flow cytometry (FC), with the outcome. CD4+ cells were the
Autor:
Raffaella Marcheselli, Attilio Guarini, Antonio Palumbo, Alessia Bari, Iolanda Vincelli, Federica Cocito, Carla Minoia, Elena Rivolti, Carla Mazzone, Alessandro Corso, Pellegrino Musto, Roberto Ria, Luigi Marcheselli, Fortunato Morabito, Giuseppe Mele, Massimo Gentile, Stefano Sacchi, Stefania Badiali, Samantha Pozzi
Publikováno v:
Europe PubMed Central
Lenalidomide and dexamethasone are an effective treatment for naive and relapsed multiple myeloma (MM) patients. Bendamustine is a good option for B-cell malignancies showing only partial cross resistance with alkylating agents used in MM patients. B
Autor:
Arne Kolstad, Harald Holte, Jan Delabie, Alexander Fosså, Waleed Ghanima, Knut Liestøl, Dlawer Abdulla Barzenje
Publikováno v:
Leukemialymphoma. 58(3)
In this study with prolonged follow up, we compared clinical outcome, including cause of death and incidence of second cancer, for patients with early stage extranodal marginal zone lymphoma (EMZL, 49 patients), nodal marginal zone lymphoma (NMZL, ni
Autor:
Rika Kawasaki, Shigeki Motomura, Sachiya Takemura, Hirotaka Takasaki, Hideyuki Koharazawa, Hirohito Sone, Taisei Suzuki, Maki Hagihara, Kenji Motohashi, Naoto Tomita, Jun Taguchi, Chizuko Hashimoto, Rika Sakai, Etsuko Yamazaki, Jun Takizawa, Shin Fujisawa, Wataru Yamamoto, Takayoshi Tachibana, Katsumichi Fujimaki, Keisuke Kawamoto, Hiroyuki Fujita, Kazuho Miyashita
Publikováno v:
Leukemialymphoma. 57(12)
We previously developed a prognostic index, SIL, which includes advanced stage (S), soluble interleukin-2 receptor level (I), and elevated lactate dehydrogenase level (L) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclo
Autor:
Bingshu E. Chen, John Kuruvilla, Kang Howson-Jan, Ralph M. Meyer, C. Tom Kouroukis, Tara Baetz, Marina S. Djurfeldt, Annette E. Hay, Rena Buckstein, Lois E. Shepherd, Stephen Couban, Massimo Federico, Michael Crump, David Szwajcer
Publikováno v:
Leukemialymphoma. 58(1)
The impact of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant (ASCT) was evaluated in a retrospective subgroup analysis of NCIC CTG LY.12. Among 414 patients who relapsed following R-CHOP, 96 received salvag
Autor:
Nigel Patton, Ian Prosser, Shir-Jing Ho, Tony Mills, John F. Seymour, Emma Link, Andrew Nicol, Diana Zannino, Mark Hertzberg, Melita Kenealy, Linda Cowan, Robin Filshie
Publikováno v:
Leukemialymphoma. 58(2)
Single agent azacitidine or immunomodulatory drugs are effective in myelodysplastic syndrome (MDS), with differing target mechanisms and toxicities. Objectives of this ALLG MDS3 study in clinically advanced MDS, AMML and low blast AML were to establi